BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 15563424)

  • 21. Systemic mastocytosis with plasma cell dyscrasia: report of a case.
    Pullarkat ST; Sedarat F; Paquette R; Said J
    Leuk Res; 2008 Jul; 32(7):1160-3. PubMed ID: 18061667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular pathological analysis of neoplastic mast cells with regard to the actual WHO classification of mast cell neoplasias].
    Sotlar K
    Verh Dtsch Ges Pathol; 2006; 90():227-35. PubMed ID: 17867601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD).
    Sotlar K; Colak S; Bache A; Berezowska S; Krokowski M; Bültmann B; Valent P; Horny HP
    J Pathol; 2010 Apr; 220(5):586-95. PubMed ID: 20112369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
    Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
    Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP; Hornick JL
    Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mast cells and mastocytosis.
    Söderholm JD
    Dig Dis; 2009; 27 Suppl 1():129-36. PubMed ID: 20203509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.
    Arock M; Akin C; Hermine O; Valent P
    Eur J Haematol; 2015 Jun; 94(6):474-90. PubMed ID: 25753531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Guidelines for the diagnosis, treatment and management of mastocytosis].
    De la Hoz B; González de Olano D; Alvarez I; Sánchez L; Núñez R; Sánchez I; Escribano L
    An Sist Sanit Navar; 2008; 31(1):11-32. PubMed ID: 18496577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels.
    Bonadonna P; Perbellini O; Passalacqua G; Caruso B; Colarossi S; Dal Fior D; Castellani L; Bonetto C; Frattini F; Dama A; Martinelli G; Chilosi M; Senna G; Pizzolo G; Zanotti R
    J Allergy Clin Immunol; 2009 Mar; 123(3):680-6. PubMed ID: 19135713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis, progression patterns and prognostication in mastocytosis.
    Sperr WR; Valent P
    Expert Rev Hematol; 2012 Jun; 5(3):261-74. PubMed ID: 22780207
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tryptase detection in bone-marrow blood: a new diagnostic tool in systemic mastocytosis.
    Proelss J; Wenzel J; Ko Y; Bieber T; Bauer R
    J Am Acad Dermatol; 2007 Mar; 56(3):453-7. PubMed ID: 17317486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic evaluation and classification of mastocytosis.
    Valent P
    Immunol Allergy Clin North Am; 2006 Aug; 26(3):515-34. PubMed ID: 16931291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mastocytosis and related entities: a practical roadmap.
    Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
    Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.
    Valent P; Sperr WR; Samorapoompichit P; Geissler K; Lechner K; Horny HP; Bennett JM
    Leuk Res; 2001 Jul; 25(7):595-602. PubMed ID: 11377685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia.
    Nagai S; Ichikawa M; Takahashi T; Sato H; Yokota H; Oshima K; Izutsu K; Hangaishi A; Kanda Y; Motokura T; Chiba S; Yatomi Y; Kurokawa M
    Exp Hematol; 2007 Nov; 35(11):1747-52. PubMed ID: 17976525
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic mastocytosis: current concepts and treatment advances.
    Tefferi A; Pardanani A
    Curr Hematol Rep; 2004 May; 3(3):197-202. PubMed ID: 15087068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.